

学校编码: 10384  
学 号: 21620120153801

分类号 \_\_\_\_\_ 密级 \_\_\_\_\_  
UDC \_\_\_\_\_

厦门大学

博士 学位 论文

醛糖还原酶的遗传缺失显著减缓了  
C57BL/6 小鼠 AngII 诱导的高血压病变进程

Aldose Reductase Deficiency Significantly Ameliorates  
Development of AngII-Induced Hypertension in C57BL/6 mice

王光辉

指导教师姓名: 杨云青教授

专业名称: 细胞生物学

论文提交日期: 2016 年 月

论文答辩时间: 2016 年 月

学位授予日期: 2016 年 月

答辩委员会主席: \_\_\_\_\_

评 阅 人: \_\_\_\_\_

2016 年 月

厦门大学博硕士论文摘要库

## 厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学术活动规范(试行)》。

另外,该学位论文为(杨云青教授)课题(组)的研究成果,获得(杨云青教授)课题(组)经费或实验室的资助,在(杨云青教授)实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,未有此项声明内容的,可以不作特别声明。)

声明人(签名):

年 月 日

厦门大学博硕士论文摘要库

## 厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

- ( ) 1. 经厦门大学保密委员会审查核定的保密学位论文，于 年 月 日解密，解密后适用上述授权。  
( ) 2. 不保密，适用上述授权。

(请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。)

声明人(签名)：

年 月 日

厦门大学博硕士论文摘要库

# 目 录

<b>目 录.....</b>	<b>I</b>
<b>Contents .....</b>	<b>I</b>
<b>缩略语对照表 .....</b>	<b>I</b>
<b>摘 要.....</b>	<b>I</b>
<b>Abstract.....</b>	<b>III</b>
<b>第一章 前 言 .....</b>	<b>1</b>
<b>    1.1 高血压 .....</b>	<b>1</b>
1.1.1 高血压与心脑血管疾病.....	1
1.1.2 高血压与肾病.....	2
1.1.3 高血压与糖尿病.....	2
<b>    1.2 高血压与肾素-血管紧张素系统 .....</b>	<b>3</b>
1.2.1 AngII 与高血压 .....	5
1.2.2 ACE2-Ang(1-7)-Mas 与高血压 .....	7
<b>    1.3 高血压与活性氧 .....</b>	<b>8</b>
1.3.1 高血压与心脏活性氧.....	10
1.3.2 高血压与肾脏活性氧.....	10
1.3.3 高血压与血管活性氧.....	12
<b>    1.4 高血压与糖代谢紊乱 .....</b>	<b>13</b>
1.4.1 高血压与果糖.....	14
1.4.2 高血压与尿酸.....	15
1.4.3 丙酮醛和末端糖基化终末产物 AGEs 对高血压的影响.....	16
<b>    1.5 多元醇途径与醛糖还原酶 .....</b>	<b>17</b>
1.5.1 多元醇途径.....	17
1.5.2 AR/PP 与糖尿病并发症 .....	18
1.5.3 AR/PP 与氧化应激 .....	19
1.5.4 AR/PP 与肾素-血管紧张素途径 .....	20

1.6 本文的研究目的及科学意义 .....	21
1.6.1 研究意义 .....	21
1.6.2 研究内容及研究目标 .....	22
<b>第二章 材料与方法 .....</b>	<b>23</b>
<b>2.1 实验材料 .....</b>	<b>23</b>
2.1.1 细胞株和菌株 .....	23
2.1.2 质粒 .....	23
2.1.3 实验动物 .....	23
2.1.4 主要试剂 .....	23
2.1.5 主要仪器 .....	26
2.1.6 常用溶液 .....	27
<b>2.2 实验方法 .....</b>	<b>30</b>
2.2.1 克隆使用的感受态细菌制备 .....	30
2.2.2 质粒 DNA 的转化与鉴定 .....	31
2.2.3 大量提取细菌质粒 DNA .....	31
2.2.4 细胞培养 .....	32
2.2.5 细胞转染 .....	33
2.2.6 RNA 抽提和荧光定量 PCR 检测 .....	34
2.2.7 蛋白质提取和 Western-blot .....	37
2.2.8 果糖处理和 Western-blot .....	38
2.2.9 小鼠尾基因组的提取以及基因组的鉴定 .....	38
2.2.10 小鼠高血压模型的建立 .....	40
2.2.11 血压的测定 .....	40
2.2.12 小鼠眼球采血提取血清 .....	41
2.2.13 果糖、山梨醇、尿酸等生化指标的测定 .....	41
2.2.14 冰冻切片制备 .....	45
2.2.15 组织包埋 .....	45
2.2.16 苏木素-伊红染色 .....	48
2.2.17 马松染色 .....	48
2.2.18 细胞内活性氧的荧光染色 .....	49
2.2.19 数据处理与统计学分析 .....	49

<b>第三章 结果与分析 .....</b>	<b>51</b>
<b>3.1 AngII/RAS 与 AR/PP 的相关性.....</b>	<b>51</b>
3.1.1 AngII 诱导细胞 AR 的 mRNA 和蛋白表达 .....	51
3.1.2 AngII 诱导小鼠组织 AR 的蛋白表达 .....	54
3.1.3 AR 表达量和活性对细胞中 <i>AT1</i> 和 <i>ACE2</i> 的 mRNA 表达水平的影响 .....	56
3.1.4 AR 表达量和活性对细胞中 <i>AT1</i> 和 <i>ACE2</i> 的蛋白表达水平的影响 .....	57
3.1.5 果糖调控 <i>AT1</i> 和 <i>ACE2</i> 蛋白的表达 .....	59
<b>3.2 AR 的缺失显著减轻 AngII 诱导的高血压.....</b>	<b>62</b>
<b>3.3 AR 缺失的高血压小鼠的大部分生理生化指标得到改善.....</b>	<b>64</b>
3.3.1 AR 缺失的高血压小鼠体重, 心重和心率没有明显改善 .....	64
3.3.2 AR 缺失的高血压小鼠山梨醇显著降低 .....	65
3.3.3 AR 缺失的高血压小鼠果糖显著降低 .....	67
3.3.4 AR 缺失的高血压小鼠 AGEs 显著降低 .....	68
3.3.5 AR 缺失的高血压小鼠尿酸显著降低 .....	70
3.3.6 AR 缺失的高血压小鼠 ROS 显著降低 .....	70
3.3.7 AR 缺失的高血压小鼠 Ang(1-7)显著升高 .....	72
<b>3.4 AR 的缺失影响了左心室和肾皮质与高血压相关 <i>AT1-ACE2</i>, <i>keap1-Nrf2</i> 和 <i>Tgfβ1</i> 的信号通路相关基因的表达 .....</b>	<b>74</b>
3.4.1 AR 的缺失影响了左心室和肾皮质 <i>AT1</i> 和 <i>ACE2</i> mRNA 的表达 .....	74
3.4.2 AR 的缺失影响了左心室和肾皮质 <i>AT1</i> 和 <i>ACE2</i> 蛋白的表达 .....	74
3.4.3 AR 的缺失影响了左心室和肾皮质 <i>Nrf2</i> 、 <i>Gclc</i> 、 <i>Gclm</i> 、 <i>Txn1</i> 和 <i>Txnr1</i> mRNA 的表达 .....	75
3.4.4 AR 的缺失影响了肾皮质 <i>Keap1</i> 、 <i>Nrf2</i> 和 <i>Tgfβ2</i> 蛋白的表达 .....	76
3.4.5 AR 的缺失影响了左心室 <i>Nrf2</i> 、 <i>Tgfβ1</i> 和 <i>Tgfβ2</i> 蛋白的表达 .....	77
<b>3.5 AR 的缺失改善了血管内膜重塑 .....</b>	<b>79</b>
<b>3.6 AR 的缺失改善了血管内膜纤维化 .....</b>	<b>81</b>
<b>3.7 AR 的缺失改善了血管内膜氧化损伤 .....</b>	<b>82</b>
<b>3.8 AR 的缺失改善了肾皮质纤维化 .....</b>	<b>83</b>
<b>3.9 AR 的缺失改善了左心室心肌纤维化 .....</b>	<b>85</b>
<b>第四章 讨论 .....</b>	<b>87</b>

<b>第五章 结论与创新点 .....</b>	<b>93</b>
<b>5.1 主要发现 .....</b>	<b>93</b>
<b>5.2 结论 .....</b>	<b>94</b>
<b>5.3 创新点 .....</b>	<b>94</b>
<b>参考文献 .....</b>	<b>95</b>
<b>致 谢 .....</b>	<b>119</b>

厦门大学博士学位论文摘要

## Contents

<b>Abbreviations .....</b>	<b>I</b>
<b>Abstract in Chinese.....</b>	<b>I</b>
<b>Abstract in English .....</b>	<b>III</b>
<b>Chapter 1 Introduction .....</b>	<b>1</b>
<b>    1.1 Hypertension .....</b>	<b>1</b>
1.1.1 Hypertension and cardiovascular diseases.....	1
1.1.2 Hypertension and renal diseases .....	2
1.1.3 Hypertension and diabetes .....	2
<b>    1.2 Hypertension and RAS .....</b>	<b>3</b>
1.2.1 AngII and hypertension.....	5
1.2.2 ACE2-Ang(1-7)-Mas and hypertension.....	7
<b>    1.3 Hypertension and ROS .....</b>	<b>8</b>
1.3.1 Hypertension and cardiac ROS.....	10
1.3.2 Hypertension and renal ROS .....	10
1.3.3 Hypertension and vascular ROS .....	12
<b>    1.4 Hypertension and disturbance of carbohydrate metabolism .....</b>	<b>13</b>
1.4.1 Hypertension and fructose .....	14
1.4.2 Hypertension and uric acid .....	15
1.4.3 MG, AGEs and hypertension.....	16
<b>    1.5 Aldose reductase and the polyol pathway .....</b>	<b>17</b>
1.5.1 The polyol pathway.....	17
1.5.2 AR/PP and diabetic complication .....	18
1.5.3 AR/PP and oxidative stress .....	19
1.5.4 AR/PP and RAS .....	20
<b>    1.6 Purpose and significance of the present study .....</b>	<b>21</b>
1.6.1 The significance of the present study.....	21
1.6.2 Purpose of the present study .....	22

<b>Chapter 2 Materials and methods.....</b>	<b>23</b>
<b>    2.1 Materials.....</b>	<b>23</b>
2.1.1 Cell lines and bacterial strain.....	23
2.1.2 Plasmids .....	23
2.1.3 Experimental animals.....	23
2.1.4 Main reagents.....	23
2.1.5 Instruments.....	26
2.1.6 Instruments.....	27
<b>    2.2 Methods .....</b>	<b>30</b>
2.2.1 The preparation of competent bacteria .....	30
2.2.2 Transformation and identification of plasmids .....	31
2.2.3 Extraction of the plasmid DNA .....	31
2.2.4 Cell culttrue.....	32
2.2.5 Transfection .....	33
2.2.6 RNA extraction and quantitative real-time PCR .....	34
2.2.7 Protein and Western-blot .....	37
2.2.8 Fructose treatment and Western-blot .....	38
2.2.9 Extraction and identification of mouse genome .....	38
2.2.10 The model of hypertension .....	40
2.2.11 The measurement of blood pressure .....	40
2.2.12 Extraction of serum.....	41
2.2.13 Biochemical analysis .....	41
2.2.14 Frozen section .....	45
2.2.15 Tissue embedding .....	45
2.2.16 Hematoxylin and Eosin staining .....	48
2.2.17 Massion staining .....	48
2.2.18 Fluorescent staining for ROS.....	49
2.2.19 Statistical analysis .....	49
<b>Chapter 3 Results.....</b>	<b>51</b>
<b>    3.1 The cross-talks between AngII/RAS and AR/PP.....</b>	<b>51</b>

3.1.1 AngII induces the expression of AR mRNA and protein in cells.....	51
3.1.2 AngII induces AR protein expression in the hypertensive mice tissues .....	54
3.1.3 Effects of AR overexpression or inhibition/knockdown on the expression of genes associated with the RAS pathway in Mes13 and MCM cells.....	56
3.1.4 Effects of AR overexpression or inhibition/knockdown on the expression of protein associated with the RAS pathway in Mes13 and MCM cells .....	57
3.1.5 Effects of fructose on the protein expression of AT1 and ACE2 .....	59
<b>3.2 AR deficiency significantly ameliorates development of AngII-induced hypertension in C57BL/6 mice .....</b>	<b>62</b>
<b>3.3 AR deficient significantly improves most of the physiological and biochemical indexes in hypertensive mice.....</b>	<b>64</b>
3.3.1 Clinical parameters have no significantly improvement in for AngII-infused KO mice .....	64
3.3.2 The levels of sorbitol in hypertensive KO mice were lower than that of hypertensive WT mice .....	65
3.3.3 The levels of fructose in hypertensive KO mice were lower than that of hypertensive WT mice .....	67
3.3.4 The levels of AGEs in hypertensive KO mice were lower than that of hypertensive WT mice .....	68
3.3.5 The levels of uric acid in hypertensive KO mice were lower than that of hypertensive WT mice .....	70
3.3.6 The levels of ROS in hypertensive KO mice were lower than that of hypertensive WT mice .....	70
3.3.7 The levels of Ang(1-7) in hypertensive KO mice were higher than that of hypertensive WT mice .....	72
<b>3.4 Amelioration in AngII-induced hypertension in AR deficient mice was associated with significantly-attenuated AT1-ACE2, Keap1-Nrf2 and Tgf<math>\beta</math>1 signaling in the renal cortex and left ventricle.....</b>	<b>74</b>
3.4.1 Effects of AR deficiency on the mRNA expression of <i>AT1</i> and <i>ACE2</i> in the heart left ventricle and renal cortex .....	74
3.4.2 Effects of AR deficiency on the protein expression of AT1 and ACE2 in the heart left ventricle and renal cortex .....	74
3.4.3 Effects of AR deficiency on the mRNA expression of <i>Nrf2</i> , <i>Gclc</i> , <i>Gclm</i> , <i>Txn1</i> and <i>Txnrd1</i> in the renal cortex and left ventricle .....	75
3.4.4 Effects of AR deficiency on the protein expression of Keap1, Nrf2 and Tgf $\beta$ 2 in the renal cortex.....	76

3.4.5 Effects of AR deficiency on the protein expression of Nrf2, Tgfb1 and Tgfb2 in the left ventricle .....	77
<b>3.5 Effects of AR deficiency on AngII-induced aorta thickness as determined by H&amp;E staining .....</b>	<b>79</b>
<b>3.6 Effects of AR deficiency on AngII-induced aorta fibrosis as determined by Masson staining .....</b>	<b>81</b>
<b>3.7 Effects of AR deficiency on AngII-induced aorta ROS production .....</b>	<b>82</b>
<b>3.8 Effects of AR deficiency on AngII-induced renal cortical fibrosis .....</b>	<b>83</b>
<b>3.9 Effects of AR deficiency on AngII-induced left ventricle fibrosis.....</b>	<b>85</b>
<b>Chapter 4 Discussion .....</b>	<b>87</b>
<b>Chapter 5 Conclusion and innovation points.....</b>	<b>93</b>
5.1 Main results.....	93
5.2 Conclusion .....	94
5.3 Innovation points .....	94
<b>References.....</b>	<b>95</b>
<b>Acknowledgements .....</b>	<b>119</b>

## 缩略语对照表

缩略语	英文	中文
ACE2	Angiotensin converting enzyme-2	血管紧张素转化酶 2
ACEI	angiotensin converting enzyme inhibitors	血管紧张素转化酶抑制剂
AGE	Advanced glycation end-product	糖基化终末端产物
AngII	Angiotensin II	血管紧张素 II
AR	Aldose reductase	醛糖还原酶
ARB	Angiotensin receptor blockers	血管紧张素受体拮抗剂
ARI	Inhibitors of angiotensin	血管紧张素抑制剂
AT1	Type I AngII receptor	血管紧张素受体 I
BP	Blood pressure	血压
BT	Bitransgenic, <i>Ar</i> <sup>-/-</sup> :: <i>KspAR</i> <sup>+/+</sup>	AR 转基因小鼠
CO	Carbon monoxide	一氧化碳
DBP	Diastolic blood pressure	舒张压
DCFH-DA	2',7'-Dichlorodihydrofluorescin diacetate	2',7'-二氯荧光素二乙酸盐
FBS	Fetal bovine serum	胎牛血清
Gclc	Glutamate-cysteine ligase catalytic subunit	谷氨酸半胱氨酸连接酶催化亚基
HO	Heme oxygenase	血红素加氧酶
HUAEC	Human umbilical artery endothelial cells	人脐动脉内皮细胞
Keap1	Kelch-like ECH-associated protein-1	Kelch 样环氧氯丙烷相关蛋白-1
KO	<i>AR</i> <sup>-/-</sup> , knockout	<i>AR</i> 敲除

MAP	Mean arterial pressure	平均动脉压
MAS	the receptor of angiotensin (1-7)	血管紧张素 (1-7) 受体
MCM	Mouse cardiomyocyte	小鼠心肌细胞
Mes13	Mouse mesangial cell	小鼠肾小球系膜细胞
NO	Nitric oxide	一氧化氮
eNOS	Endothelial nitric oxide synthase	内皮型一氧化氮合酶
PP	The polyol pathway	山梨醇通路
RFU	Relative fluorescence unit	相对荧光单位
RAS	Renin-angiotensin system	肾素-血管紧张素系统
ROS	Reactive oxygen species	活性氧
RT-PCR	Reverse-transcriptase polymerase chain reaction	逆转录聚合酶链反应
SBP	Systolic blood pressure	收缩压
SHR	Spontaneously hypertensive rats	自发性高血压大鼠
SOD3	Superoxide dismutase 3	超氧化物歧化酶 3
Tgf $\beta$ 1	Transforming growth factor $\beta$ -1	转化生长因子 1
Tgf $\beta$ 2	Transforming growth factor $\beta$ -2	转化生长因子 2
WT	Wild-type	野生型

Degree papers are in the “[Xiamen University Electronic Theses and Dissertations Database](#)”.

Fulltexts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to [etd@xmu.edu.cn](mailto:etd@xmu.edu.cn) for delivery details.